We have reported that CE-US coupled with hemodynamics is useful in the diagnosis of pancreatic diseases, in particular the differentiation between pancreatic mass and cystic lesions, like pancreatic cancer and mass-forming pancreatitis in mass lesions, and the evaluation of the level of cancer progression. However, in evaluating the hemodynamics that reflects tissue conditions, the use of the high MI contrast agent, Levovist
® has had limitations and therefore a precise evaluation was difficult. Thus, a new ultrasonography technique using the second generation low MI contrast agent, Sonazoid
® was developed. The aim of our study is to evaluate whether this new sonography technique will be able to be applied in pancreatic diseases, and to compare it with CE-US using the conventional contrast agent, Levovist
®.
The results of pancreatic diseases in which Sonazoid
® was used showed that on the whole, more detailed contrast images were obtained compared to Levovist
®. Moreover, contrast evaluations that were more precise, compared to previous methods, were possible. In addition, detailed movements of microbubbles in the capillaries that were difficult to visualize with Levovist
® could be visualized repeatedly in real-time with Sonazoid
®. The performance of CE-US in pancreatic diseases was greatly improved when Sonazoid
® was used compared to the conventional method using Levovist
®, and was therefore favorable in the differential diagnosis.
View full abstract